Type 2 Diabetes

Clinical trial initiated for type 2 diabetes treatment

Published in Obesity and Diabetes Week, February 2nd, 2004

Tularik Inc. (TLRK) announced the recent initiation of a phase II efficacy and safety study with T131 for the treatment of patients with type 2 (insulin resistant) diabetes mellitus.

T131, an orally administered therapy, is expected to lower blood glucose in diabetic patients by improving the body's ability to respond to insulin.

This phase II, double-blind, placebo-controlled study will enroll approximately 60 type 2 diabetic patients whose blood glucose has not been adequately controlled with diet and exercise.

Patients will receive T131 or placebo once daily for 28 days. The effectiveness of T131 will be assessed by measuring...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry